• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

使用患者报告结局测量信息系统(PROMIS)对腱鞘巨细胞瘤(TGCT)患者的身体功能进行测量。

The measurement of physical functioning among patients with Tenosynovial Giant Cell Tumor (TGCT) using the Patient-Reported Outcomes Measurement Information System (PROMIS).

作者信息

Gelhorn Heather L, Ye Xin, Speck Rebecca M, Tong Sandra, Healey John H, Bukata Susan V, Lackman Richard D, Murray Lindsey, Maclaine Grant, Lenderking William R, Hsu Henry H, Lin Paul S, Tap William D

机构信息

Evidera, 7101 Wisconsin Avenue, Suite 1400, Bethesda, MD, 20814, USA.

Daiichi Sankyo Pharma Development, 399 Thornall St, Edison, NJ, 08837, USA.

出版信息

J Patient Rep Outcomes. 2019 Feb 4;3(1):6. doi: 10.1186/s41687-019-0099-0.

DOI:10.1186/s41687-019-0099-0
PMID:30714073
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6360193/
Abstract

BACKGROUND

Tenosynovial giant cell tumor (TGCT), a rare, locally aggressive neoplasm of the synovium of joints and tendon sheaths, is associated with joint destruction, pain and swelling. Impacts on physical function (PF) vary depending on tumor size and location. The aim of this study was to identify relevant items, and demonstrate the content validity of custom measures of lower extremity PF from the Patient-Reported Outcomes Measurement Information System Physical Function Physical Function (PROMIS-PF) item bank among patients with TGCT.

METHODS

Patients were recruited for qualitative research interviews to identify predominant TGCT symptoms and impacts. Patients completed a checklist to evaluate the relevance of each PROMIS-PF item. The publicly available PROMIS-PF item response theory (IRT) parameters were used to select items representing the range of the latent PF trait.

RESULTS

Participants (n = 20) were 75% female, mean age 42.5 years. TGCTs were located in the knee (n = 15), hip (n = 3), and ankle (n = 2). Fifty-four PROMIS-PF items were identified as relevant by ≥20% of the participants. PF concepts discussed by participants during the qualitative interviews were also used to select relevant items. Selected items (n = 13) were used to create a physical function subscale specific to lower extremity tumors.

CONCLUSIONS

We describe a novel method of combining qualitative research and IRT-based item information to select a relevant and content valid subset of PROMIS-PF items to assess heterogeneous impacts on PF in TGCT, a rare disease population.

摘要

背景

腱鞘巨细胞瘤(TGCT)是一种罕见的、局部侵袭性的关节和腱鞘滑膜肿瘤,与关节破坏、疼痛和肿胀相关。对身体功能(PF)的影响因肿瘤大小和位置而异。本研究的目的是识别相关条目,并在TGCT患者中验证来自患者报告结局测量信息系统身体功能(PROMIS-PF)条目库的定制下肢PF测量指标的内容效度。

方法

招募患者进行定性研究访谈,以确定TGCT的主要症状和影响。患者完成一份清单,以评估每个PROMIS-PF条目的相关性。使用公开可用的PROMIS-PF条目反应理论(IRT)参数来选择代表潜在PF特质范围的条目。

结果

参与者(n = 20)中75%为女性,平均年龄42.5岁。TGCT位于膝关节(n = 15)、髋关节(n = 3)和踝关节(n = 2)。54个PROMIS-PF条目被≥20%的参与者确定为相关。定性访谈中参与者讨论的PF概念也用于选择相关条目。选择的条目(n = 13)用于创建特定于下肢肿瘤的身体功能子量表。

结论

我们描述了一种新方法,将定性研究与基于IRT的条目信息相结合,以选择相关且内容有效的PROMIS-PF条目子集,来评估TGCT(一种罕见疾病群体)对PF的异质性影响。

相似文献

1
The measurement of physical functioning among patients with Tenosynovial Giant Cell Tumor (TGCT) using the Patient-Reported Outcomes Measurement Information System (PROMIS).使用患者报告结局测量信息系统(PROMIS)对腱鞘巨细胞瘤(TGCT)患者的身体功能进行测量。
J Patient Rep Outcomes. 2019 Feb 4;3(1):6. doi: 10.1186/s41687-019-0099-0.
2
Patient-reported Symptoms of Tenosynovial Giant Cell Tumors.患者报告的腱鞘巨细胞瘤症状。
Clin Ther. 2016 Apr;38(4):778-93. doi: 10.1016/j.clinthera.2016.03.008. Epub 2016 Apr 1.
3
The Patient Perspective on the Impact of Tenosynovial Giant Cell Tumors on Daily Living: Crowdsourcing Study on Physical Function and Quality of Life.患者对腱鞘巨细胞瘤对日常生活影响的看法:关于身体功能和生活质量的众包研究
Interact J Med Res. 2018 Feb 23;7(1):e4. doi: 10.2196/ijmr.9325.
4
Psychometric properties of a custom Patient-Reported Outcomes Measurement Information System (PROMIS) physical function short form and worst stiffness numeric rating scale in tenosynovial giant cell tumors.定制的患者报告结局测量信息系统(PROMIS)身体功能简表和腱鞘巨细胞瘤中最差僵硬数字评定量表的心理测量特性
J Patient Rep Outcomes. 2020 Jul 16;4(1):61. doi: 10.1186/s41687-020-00217-6.
5
Development of a Patient-Reported Outcomes Measurement Information System (PROMIS®) short form for measuring physical function in geriatric rehabilitation patients.开发用于评估老年康复患者身体功能的患者报告结局测量信息系统(PROMIS®)简短形式。
Qual Life Res. 2020 Sep;29(9):2563-2572. doi: 10.1007/s11136-020-02506-5. Epub 2020 Apr 21.
6
Physical function metric over measure: An illustration with the Patient-Reported Outcomes Measurement Information System (PROMIS) and the Functional Assessment of Cancer Therapy (FACT).测量之上的身体功能指标:以患者报告结局测量信息系统(PROMIS)和癌症治疗功能评估(FACT)为例
Cancer. 2018 Jan 1;124(1):153-160. doi: 10.1002/cncr.30981. Epub 2017 Sep 8.
7
Improved responsiveness and reduced sample size requirements of PROMIS physical function scales with item response theory.使用项目反应理论提高 PROMIS 身体功能量表的反应性和减少样本量需求。
Arthritis Res Ther. 2011;13(5):R147. doi: 10.1186/ar3461. Epub 2011 Sep 14.
8
Individuals with knee impairments identify items in need of clarification in the Patient Reported Outcomes Measurement Information System (PROMIS®) pain interference and physical function item banks - a qualitative study.膝关节功能障碍患者明确患者报告结局测量信息系统(PROMIS®)疼痛干扰和身体功能条目库中需要澄清的条目——一项定性研究。
Health Qual Life Outcomes. 2016 May 11;14:77. doi: 10.1186/s12955-016-0478-7.
9
The diffuse-type tenosynovial giant cell tumor (dt-TGCT) patient journey: a prospective multicenter study.弥漫型腱鞘巨细胞瘤(dt-TGCT)患者的诊治历程:一项前瞻性多中心研究。
Orphanet J Rare Dis. 2021 Apr 29;16(1):191. doi: 10.1186/s13023-021-01820-6.
10
Upper-extremity and mobility subdomains from the Patient-Reported Outcomes Measurement Information System (PROMIS) adult physical functioning item bank.患者报告的结局测量信息系统(PROMIS)成人身体功能项目库中的上肢和活动能力子领域。
Arch Phys Med Rehabil. 2013 Nov;94(11):2291-6. doi: 10.1016/j.apmr.2013.05.014. Epub 2013 Jun 8.

引用本文的文献

1
Real-world experience of patients newly initiated on pexidartinib for tenosynovial giant cell tumor.培西达替尼新用于腱鞘巨细胞瘤患者的真实世界经验。
Future Oncol. 2025 Jul 4:1-10. doi: 10.1080/14796694.2025.2527586.
2
Patient-reported continued benefits of pexidartinib for tenosynovial giant cell tumor based on a real-world study in the United States.基于美国一项真实世界研究,患者报告培西达替尼对腱鞘巨细胞瘤持续有效。
Oncologist. 2025 Mar 10;30(3). doi: 10.1093/oncolo/oyaf028.
3
Observational study of the Amaze™ asthma disease management platform.对Amaze™哮喘疾病管理平台的观察性研究。
Digit Health. 2024 Oct 22;10:20552076241282380. doi: 10.1177/20552076241282380. eCollection 2024 Jan-Dec.
4
Vimseltinib versus placebo for tenosynovial giant cell tumour (MOTION): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.维莫非尼对比安慰剂治疗腱鞘巨细胞瘤(MOTION):一项多中心、随机、双盲、安慰剂对照的 3 期临床试验。
Lancet. 2024 Jun 22;403(10445):2709-2719. doi: 10.1016/S0140-6736(24)00885-7. Epub 2024 Jun 3.
5
Real-World Patient Experience of Pexidartinib for Tenosynovial Giant-Cell Tumor.真实世界中培昔利珠单抗治疗腱鞘巨细胞瘤患者的体验。
Oncologist. 2024 Apr 4;29(4):e535-e543. doi: 10.1093/oncolo/oyad282.
6
Current therapies and future prospective for locally aggressive mesenchymal tumors.局部侵袭性间充质肿瘤的当前治疗方法及未来展望
Front Oncol. 2023 Jul 21;13:1160239. doi: 10.3389/fonc.2023.1160239. eCollection 2023.
7
PROMIS Profile-29 is a valid instrument with distinct advantages over legacy instruments for measuring the quality of life in chronic liver disease.PROMIS Profile-29 是一种有效的工具,与传统工具相比,它在测量慢性肝病患者的生活质量方面具有明显的优势。
Hepatology. 2023 Dec 1;78(6):1788-1799. doi: 10.1097/HEP.0000000000000480. Epub 2023 May 25.
8
Tenosynovial Giant Cell Tumor Observational Platform Project (TOPP) Registry: A 2-Year Analysis of Patient-Reported Outcomes and Treatment Strategies.腱膜巨细胞瘤观察平台项目(TOPP)注册研究:患者报告结局和治疗策略的 2 年分析。
Oncologist. 2023 Jun 2;28(6):e425-e435. doi: 10.1093/oncolo/oyad011.
9
Complementary Effects of Surgery and Pexidartinib in the Management of Patients with Complex Diffuse-Tenosynovial Giant Cell Tumor.手术与培西达替尼联合治疗复杂弥漫性腱鞘巨细胞瘤患者的互补作用
Case Rep Orthop. 2022 Dec 3;2022:7768764. doi: 10.1155/2022/7768764. eCollection 2022.
10
A prospective real-world study of the diffuse-type tenosynovial giant cell tumor patient journey: A 2-year observational analysis.弥漫型腱鞘巨细胞瘤患者就诊历程的前瞻性真实世界研究:2 年观察性分析。
J Surg Oncol. 2022 Dec;126(8):1520-1532. doi: 10.1002/jso.27067. Epub 2022 Aug 25.

本文引用的文献

1
Patient-reported Symptoms of Tenosynovial Giant Cell Tumors.患者报告的腱鞘巨细胞瘤症状。
Clin Ther. 2016 Apr;38(4):778-93. doi: 10.1016/j.clinthera.2016.03.008. Epub 2016 Apr 1.
2
Current Systemic Treatment Options for Tenosynovial Giant Cell Tumor/Pigmented Villonodular Synovitis: Targeting the CSF1/CSF1R Axis.腱鞘巨细胞瘤/色素沉着绒毛结节性滑膜炎的当前全身治疗选择:靶向集落刺激因子1/集落刺激因子1受体轴
Curr Treat Options Oncol. 2016 Feb;17(2):10. doi: 10.1007/s11864-015-0385-x.
3
Validity and measurement precision of the PROMIS physical function item bank and a content validity-driven 20-item short form in rheumatoid arthritis compared with traditional measures.在类风湿关节炎中,PROMIS 物理功能项目库及其内容有效性驱动的 20 项简短形式与传统测量方法的有效性和测量精度比较。
Rheumatology (Oxford). 2015 Dec;54(12):2221-9. doi: 10.1093/rheumatology/kev265. Epub 2015 Jul 29.
4
Structure-Guided Blockade of CSF1R Kinase in Tenosynovial Giant-Cell Tumor.结构导向的 CSF1R 激酶阻断在腱鞘巨细胞瘤中的应用。
N Engl J Med. 2015 Jul 30;373(5):428-37. doi: 10.1056/NEJMoa1411366.
5
The growing problem of benign connective tissue tumours.良性结缔组织肿瘤日益严重的问题。
Lancet Oncol. 2015 Aug;16(8):879-80. doi: 10.1016/S1470-2045(15)00147-3. Epub 2015 Jul 12.
6
Long-term follow-up results of primary and recurrent pigmented villonodular synovitis.原发性及复发性色素沉着绒毛结节性滑膜炎的长期随访结果
Rheumatology (Oxford). 2014 Nov;53(11):2063-70. doi: 10.1093/rheumatology/keu230. Epub 2014 Jun 10.
7
Responsiveness and minimally important difference for the patient-reported outcomes measurement information system (PROMIS) 20-item physical functioning short form in a prospective observational study of rheumatoid arthritis.类风湿关节炎前瞻性观察研究中患者报告结局测量信息系统(PROMIS)20项身体功能简表的反应性及最小重要差异
Ann Rheum Dis. 2015 Jan;74(1):104-7. doi: 10.1136/annrheumdis-2013-204053. Epub 2013 Oct 4.
8
Testing measurement invariance of the patient-reported outcomes measurement information system pain behaviors score between the US general population sample and a sample of individuals with chronic pain.检验患者报告结局测量信息系统疼痛行为评分在美国一般人群样本和慢性疼痛患者样本中的测量不变性。
Qual Life Res. 2014 Feb;23(1):239-44. doi: 10.1007/s11136-013-0463-0. Epub 2013 Jul 4.
9
Validation of PROMIS ® Physical Function computerized adaptive tests for orthopaedic foot and ankle outcome research.验证 PROMIS ® 物理功能计算机自适应测试在矫形足踝结果研究中的应用。
Clin Orthop Relat Res. 2013 Nov;471(11):3466-74. doi: 10.1007/s11999-013-3097-1.
10
A lower extremity physical function computerized adaptive testing instrument for orthopaedic patients.一种用于矫形患者的下肢身体功能计算机自适应测试仪器。
Foot Ankle Int. 2012 Apr;33(4):326-35. doi: 10.3113/FAI.2012.0326.